Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

14:40
11/20/16
11/20
14:40
11/20/16
14:40

Retrophin reports additional Phase 2 data on sparsentan in glomerulosclerosis

Retrophin announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder. The new findings are being presented at the American Society of Nephrology Kidney Week. As announced in September, top-line data from DUET showed the sparsentan treatment group achieved statistical significance in the study's primary efficacy endpoint, reduction of proteinuria. An analysis of the secondary endpoint presented Saturday showed that a "significantly greater" proportion of patients receiving sparsentan achieved modified partial remission of proteinuria versus irbesartan patients. In addition, four patients receiving sparsentan achieved complete remission as compared to zero irbesartan patients. Also presented Saturday was a post-hoc, intention-to-treat analysis showing that the sparsentan treatment group again demonstrated a greater than two-fold reduction of proteinuria versus irbesartan. Further analysis of the safety database from the initial eight-week, double-blind treatment period also showed sparsentan was generally safe and well-tolerated. Detailed results of the above-mentioned findings include: "An analysis of the secondary endpoint, which showed that after the eight-week, double-blind treatment period, 28.1% of patients receiving sparsentan achieved modified partial remission of proteinuria, compared to 9.4% of irbesartan-treated patients. The proportion of patients achieving modified partial remission increased during the open label period. After 48 weeks of treatment with sparsentan, 57.7% of patients achieved modified partial remission. In addition, 50% of patients that transferred from irbesartan to sparsentan at the beginning of the open label period achieved modified partial remission after 40 weeks of treatment. Complete remission, defined as proteinuria less than 0.3 g/g, was achieved by four patients receiving sparsentan during the eight-week, double-blind treatment period, compared to zero irbesartan-treated patients. A post-hoc ITT analysis showed a statistically significant difference in the mean reduction of proteinuria from baseline for the sparsentan treatment group compared to the irbesartan group after the study's eight-week, double-blind treatment period. The sparsentan group achieved a 42.7% mean reduction of proteinuria compared to 15.7% for the irbesartan group. The ITT analysis also showed that after eight weeks of treatment with 400 mg and 800 mg of sparsentan, the mean reduction of proteinuria from baseline was 44.8%, compared to 15.9% for the irbesartan-treated patients in these two cohorts. During the eight-week, double-blind period, the incidence of treatment-emergent adverse events for the sparsentan group was similar to the irbesartan group, except for edema. The severity of edema did not significantly worsen from baseline and no patients withdrew from the study as a result of edema during the eight-week, double-blind treatment period... The incidence of serious adverse events was similar across both groups. Eighty-four percent of patients who completed the eight-week, double-blind treatment period continue to receive sparsentan in the open-label extension."

RTRX Retrophin
$20.08

-1.31 (-6.12%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
LEER
09/07/16
NO CHANGE
LEER
Outperform
Retrophin price target raised to $32 from $27 at Leerink
Leerink analyst Joseph Schwartz said he is "very optimistic" that sparsentan will be approved after Retrophin announced top-line results for its Phase 2b DUET study. However, he thinks it is still unclear if the results reported today will be enough to support accelerated approval or if another clinical trial will be required. Schwartz raised his price target on Retrophin to $32 from $27 following the data release and keeps an Outperform rating on the shares.
09/08/16
BMOC
09/08/16
NO CHANGE
BMOC
Retrophin price target raised to $40 from $28 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company reported Phase II data for its Sparsentan drug that the analyst views positively. Kim now sees a 45% chance of success for the drug, up from 25% previously. The analyst keeps an Outperform rating on the shares.
11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$227.58

7.12 (3.23%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HSGX

Histogenics

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics 2.34M share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GAIA

Gaia

$11.90

-0.05 (-0.42%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Conference/Events
Gaia management to meet with B. Riley »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

07:20
01/23/18
01/23
07:20
01/23/18
07:20
General news
Treasury Market Outlook: global yields tracked lower overnight »

Treasury Market Outlook:…

07:18
01/23/18
01/23
07:18
01/23/18
07:18
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

STT

State Street

$108.99

1.38 (1.28%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Hot Stocks
State Street sees Beacon savings realized 18 months ahead of plan by mid-2019 »

In slides ahead of its Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

W

Wayfair

$90.64

2.8 (3.19%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

07:16
01/23/18
01/23
07:16
01/23/18
07:16
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

VYGR

Voyager Therapeutics

$20.23

1.56 (8.36%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Hot Stocks
Voyager Therapeutics announces FDA clearance of VY-AADC IND application »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$37.00

1 (2.78%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Upgrade
Triumph Bancorp rating change  »

Triumph Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Conference/Events
Boston University to release survey »

Boston University…

CAT

Caterpillar

$170.89

0.48 (0.28%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Upgrade
Caterpillar rating change  »

Caterpillar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

GPRO

GoPro

$6.30

0.01 (0.16%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Downgrade
GoPro rating change  »

GoPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:11
01/23/18
01/23
07:11
01/23/18
07:11
Periodicals
Verizon mulls sports gambling as legalization nears, Bloomberg reports »

Verizon is mulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

, JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Recommendations
Sorrento Therapeutics, Juno Therapeutics, Celgene analyst commentary  »

Juno acquisition bodes…

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 16

    Feb

  • 28

    Feb

  • 25

    Mar

SPX

S&P 500

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

, ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Conference/Events
U.S. Capital Advisors to hold a conference »

Midstream Corporate…

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 26

    Feb

ACBFF

Aurora Cannabis

$11.65

0.8799 (8.17%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Hot Stocks
Aurora Cannabis, CanniMed extending standstill agreement »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.71

0.06 (0.25%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon up marginally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

AOS

A.O. Smith

$67.00

-0.04 (-0.06%)

, JCI

Johnson Controls

$39.20

0.3 (0.77%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Conference/Events
KeyBanc to hold company meetings at expo »

KeyBanc Company Meetings…

AOS

A.O. Smith

$67.00

-0.04 (-0.06%)

JCI

Johnson Controls

$39.20

0.3 (0.77%)

RBC

Regal Beloit

$79.20

-0.2 (-0.25%)

WTS

Watts Water

$79.65

-0.85 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 06

    Feb

  • 13

    Feb

  • 22

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Verizon sees positive impact to cash flow from operations from tax reform »

Tax-reform legislation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

GLD

SPDR Gold Trust

$126.65

0.23 (0.18%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Conference/Events
Goldman Sachs to hold a conference »

Fintech Conference 2018…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.